A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer

The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy tissues. Here, we describe TNB-928B, a fully human...

Descripción completa

Detalles Bibliográficos
Autores principales: Avanzino, Brian C., Prabhakar, Kirthana, Dalvi, Pranjali, Hartstein, Sharon, Kehm, Hannes, Balasubramani, Aarti, Boudreau, Andrew A., Buelow, Ben, Chang, Karen, Davison, Laura M., Iyer, Suhasini, Kalwit, Vidyut, Lewis Wilson, Kristin, Malik-Chaudhry, Harbani K., Pierson, Will, Pineda, Geovanni, Rangaswamy, Udaya S., Saiganesh, Sowmya, Schellenberger, Ute, Ugamraj, Harshad S., Yabut, Rodolfovan D., Buelow, Roland, Chapman, Jocelyn, Trinklein, Nathan D., Harris, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397469/
https://www.ncbi.nlm.nih.gov/pubmed/36016696
http://dx.doi.org/10.1080/2162402X.2022.2113697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397469/
https://www.ncbi.nlm.nih.gov/pubmed/36016696
http://dx.doi.org/10.1080/2162402X.2022.2113697

Ejemplares similares